Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT00826384
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Brief Summary
According to radiology imaging, the patients of HCC are divided into two groups(hypovascular tumor group and moderately vascular tumor group). Every group is divided into TACE therapy with balloon catheter subgroup and regular TACE therapy subgroup. Patients take the TACE therapy each 45 days, and have MRI diffusion examine or CT one week before next therapy. All objects are observed until the end event happening or in the group for 6 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 352
Inclusion Criteria
- sign the written informed consent form provided.
- diagnosed clinically as HCC,need to take TACE.
Exclusion Criteria
- have had an allergic reaction following iodine.
- have been in any TACE or radiotherapy or biotherapy within 30 days before the study.
- HCC of diffuse type,failure of hepatic function, chronic illness or disease including failure of heart function, uncontrolled high blood pressure, heart disorders, serious infection, uncontrolled diabetes mellitus.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Overall survival 2010
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Eastern hepatobilliary surgery hospital
🇨🇳Shanghai, Shanghai, China